Vuno, a medical AI company, has secured strategic participation from the $6.8 million USD (10 billion KRW) Smilegate Innovation Growth Fund managed by Smilegate Investment. The capital is being raised through a perpetual convertible bond structure as part of Vuno’s strategy to strengthen long-term business stability and global expansion capabilities.

Smilegate Investment previously participated as an early investor before Vuno’s IPO and successfully exited. After four years, the firm is expanding its partnership again to support Vuno’s mid to long-term growth strategy.

“Vuno has proven its growth potential by securing a clear technological advantage in Korea’s medical AI market,” said a Smilegate Investment representative. “We decided to participate in this fund based on our positive assessment of the accelerating pace of business in key markets including the United States and Europe.”

Vuno plans to further strengthen its business execution capabilities in overseas markets with this support. The company is currently awaiting results for FDA 510k clearance and New Technology Add-on Payment (NTAP) application review for its flagship product VUNO Med®-DeepCARS® in the United States. At the same time, Vuno is pursuing European and Middle Eastern market expansion based on contracts with multiple local partners. The strategy is to strengthen overseas business operations and emerge as a global medical AI company.

“Partnering with Smilegate Investment again reflects confidence in Vuno’s technological competitiveness and global growth potential,” said a Vuno representative. “We will expand our influence as a global medical AI company by demonstrating both clinical and commercial value in overseas markets.”